| HS Code | 925720 |
| Product Name | Combined Newcastle Disease and Egg Drop Syndrome Vaccine, Inactivated Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions |
| Api Type | Inactivated whole-virus vaccine antigen concentrate |
| Target Diseases | Newcastle Disease and Egg Drop Syndrome |
| Active Antigens | Newcastle disease virus (NDV) and Egg Drop Syndrome virus (EDS-76 adenovirus) |
| Inactivation Method | Chemical inactivation, typically with beta-propiolactone or formalin |
| Veterinary Species | Poultry, primarily chickens and laying hens |
| Adjuvant System | Formulable with oil emulsion or aluminum hydroxide adjuvants |
| Routes Of Administration | Suitable for intramuscular or subcutaneous injection upon final formulation |
| Dosage Form Compatibility | Tablets, injections, capsules, powders, granules, premix, and solutions |
| Vaccine Type | Combined inactivated veterinary vaccine |
| Preservatives | May include thimerosal or other veterinary-acceptable preservatives when formulated |
| Storage Requirements | Store at 2°C to 8°C, protected from light and freezing |
| Shelf Life | Approximately 12 to 24 months when stored under recommended conditions |
| Withdrawal Period | Zero days when used as a licensed veterinary vaccine according to label instructions |
| Packaging Options | Sealed sterile glass vials, ampoules, or aluminum laminate containers suitable for API handling |
As an accredited Combined Newcastle Disease and Egg Drop Syndrome Vaccine,Inactivated Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Packaged in sterile, airtight multi-dose vials or sealed drums; each unit contains 1000 mL (1 L) of inactivated veterinary vaccine API. |
| Container Loading (20′ FCL) | Loading of one 20-foot container (FCL) with Combined Newcastle Disease and Egg Drop Syndrome Vaccine, inactivated, veterinary-grade API for pharmaceutical formulations. |
| Shipping | Shipping requires strict cold-chain management at 2–8°C to maintain potency. Supplied as veterinary-grade API, it must be packed in sealed, insulated containers with temperature loggers. Handle carefully, avoid freeze-thaw cycles, and ensure compliance with international biologics transport regulations for safe, traceable delivery. |
| Storage | Store the inactivated vaccine API at 2–8°C in a refrigerator. Keep in tightly sealed, original containers protected from light, moisture, and heat. Do not freeze, as freezing may damage potency. Store away from incompatible substances and ensure good ventilation. Handle using aseptic precautions and observe expiry dates. |
| Shelf Life | Shelf life is typically 18–24 months when stored at 2–8°C, protected from light and freezing. |
The primary downstream formulation route for combined inactivated Newcastle disease virus (NDV) and egg drop syndrome virus (EDSV) antigen concentrates is a sterile water-in-oil (W/O) emulsion filled into single-dose or multidose glass vials for intramuscular injection in replacement pullets, layers, and breeder flocks. The aqueous phase typically contains phosphate-buffered saline at pH 7.2 ± 0.2 with antigen concentrate volume fractions of 20–40% v/v, while the oil phase is based on light liquid paraffin at 60–70% v/v and mannide oleate as the emulsifying surfactant at 6–10% v/v. Before emulsification, the antigen concentrate must be released with a pre-inactivation NDV titre sufficient to meet the inactivated vaccine potency requirements of Ph. Eur. 0870 and a haemagglutinating EDSV titre standardised according to Ph. Eur. 0582. The oil phase viscosity before emulsification is typically controlled at 10–30 mPa·s at 40°C by ASTM D445, and the final emulsion viscosity after mixing is normally 20–80 mPa·s at 20°C by rotational rheometry. The two phases are mixed under a rotor–stator homogeniser at 3,000–6,000 rpm for 5–15 min, with jacket cooling holding the bulk temperature at or below 25°C; higher temperatures reduce EDSV haemagglutination activity. The resulting emulsion shows a median droplet diameter D50 of 0.8–2.5 µm. Finished product is filled as a ready-to-use injection with an administration volume of 0.5 mL per bird, given intramuscularly or subcutaneously at 16–20 weeks of age after live NDV priming.
In subcutaneous revaccination programs where injection-site swelling is a reported batch-rejection criterion, a water-in-oil-in-water (W/O/W) double emulsion is prepared by first generating a primary W/O emulsion at an internal aqueous phase fraction of 20–30% v/v and then dispersing this primary emulsion into an external aqueous phase containing polysorbate 80 at 0.5–2.0% w/v under paddle mixing at 200–500 rpm. The internal aqueous phase cannot exceed 30% v/v without transforming the primary emulsion into an unstable high-internal-phase system when the external phase contains sodium chloride at 0.9% w/v; osmotic swelling of the internal droplets increases the D50 from 1.5 µm to 2.8 µm within 2 h if the external phase is hypotonic. Secondary emulsification time is limited to 5 min because extended shear strips the surfactant from the primary droplet interface and releases antigen into the external aqueous phase. The terminal W/O/W emulsion is filled at 0.25–0.5 mL per dose and shows a lower viscosity of 5–15 mPa·s at 20°C, which permits injection through a 23–25 gauge needle. Published data for the specific combination of NDV and EDSV in W/O/W systems is limited; formulators must verify that EDSV haemagglutination titre is not reduced by the secondary emulsification step, because the antigen can partition into the aqueous–oil interface and become inaccessible to the immune system.
For multivalent inactivated vaccines that carry NDV, EDSV, infectious bronchitis virus, avian metapneumovirus, and reovirus components, the aqueous phase blending order is controlled by the flocculation threshold of the egg-derived proteins present in the EDSV antigen concentrate. When the EDSV antigen concentrate contributes more than 0.5 mg/mL of total protein to the final aqueous phase, oil emulsification at the standard mannide oleate concentration of 6–10% v/v can produce visible aggregate formation within 30 days at 37°C accelerated storage, and the emulsion creaming rate rises from 0.2 mm/day to 1.5 mm/day during this period. To prevent this, the EDSV antigen is diluted to a working protein concentration below the threshold before the NDV antigen concentrate is added, and the entire aqueous phase is adjusted to pH 7.0–7.4 with phosphate buffer before the oil phase is metered in. Preservative selection is constrained: thimerosal at standard concentrations can reduce EDSV haemagglutination titre by more than 1 log2 after 7 days in aqueous storage at 2–8°C, whereas phenol at 0.1% w/v is better tolerated if the residual formaldehyde in the API is first neutralised with sodium metabisulfite at a molar ratio of 1.2:1. Final potency testing for the combined product is performed on the emulsified bulk rather than on the aqueous blend, because the oil phase contributes a depot effect that modifies the apparent potency in challenge tests. The terminal product is filled as a polyvalent inactivated injection and administered at 0.5 mL per bird, with the NDV component retaining not less than 80% of its pre-emulsification titre after 24 months at 2–8°C.
In continuous manufacturing lines that produce 2,000 L or larger finished vaccine batches, the aqueous antigen premix is prepared in a chilled stainless-steel vessel at 50–100 rpm bottom agitation and then metered with a positive displacement pump into a static mixer containing 32 elements. The oil adjuvant premix is simultaneously metered by a gear pump at 2–8 L/min, and the combined stream passes through an in-line rotor–stator homogeniser before the bulk enters a surge tank. Pressure drop across the static mixer is maintained at 0.5–1.5 bar; when the pressure exceeds 2.0 bar, the downstream 200 µm polishing screen is typically fouled by denatured protein aggregates, leading to batch rejection or rework. The antigen premix must be filtered through a 5 µm depth filter before entering the static mixer to remove flocculates that form if residual formaldehyde exceeds 0.05% w/v and then reacts with mannide oleate. After mixing, the bulk is recirculated for 2–4 passes to narrow droplet size distribution and then cooled to 15–20°C before sterile filling into Type I glass vials or siliconised prefilled syringes. This continuous premix configuration reduces batch time compared with vessel-based emulsification but is less tolerant of phase ratio drift; the oil fraction must be held within ±2% of the target value to prevent creaming instability in the finished product.
Solid oral dosage forms are absent from Ph. Eur. 0870 and Ph. Eur. 0582 for mechanistic reasons rather than commercial preference. Compression of an antigen-containing matrix at 5–20 kN with direct compression grades of microcrystalline cellulose and lactose generates localised frictional temperatures above 40°C, which denature the NDV fusion protein and reduce EDSV haemagglutination titre by more than 2 log2 after compression. Capsule filling with powder blends containing starch and magnesium stearate exposes the antigen to a dry environment with moisture content below 2% w/w, which collapses the lipid envelope and eliminates antigenicity; the inactivated antigen cannot be reconstituted to an immunogenic state after such dehydration. Feed premix application is also excluded because inactivated NDV and EDSV particles are not absorbed across the avian intestinal epithelium in sufficient quantity to induce protective antibody, and the oil-adjuvanted emulsion would be destroyed by gastric pH 2–4 and bile salt emulsification. Published data for this specific configuration is limited, and no ISO/ASTM method exists for dissolution testing of a vaccine antigen tablet because the required analytical acceptance criteria—specific antibody titre—cannot be translated into a conventional dissolution profile. The only validated solid-related step in downstream processing is freeze-thaw stability of the aqueous antigen bulk during storage at -20°C when formulated with 5% w/v sucrose and 2% w/v lactalbumin hydrolysate; this is a storage stabiliser, not a tablet or capsule excipient system.
Because the lipid-enveloped NDV particle is 100–300 nm and the EDSV particle is 70–90 nm in diameter, terminal sterile filtration through a 0.22 µm membrane is not feasible without major antigen loss; industrial practice therefore relies on inactivation of the bulk, aseptic processing, and preservative-containing formulations. The aqueous antigen phase is clarified with a 1.0 µm glass fibre depth filter to reduce aggregates while allowing virus particles to pass into the filtrate; flux is typically maintained at 50–150 L/m²/h at 0.2–0.5 bar transmembrane pressure. Sterility of the filtered aqueous phase is not assumed because the filter is not sterilising for the antigen; the final emulsion is instead released by the sterility test described in Ph. Eur. 2.6.1 after at least 14 days incubation. The filling line uses single-use peristaltic tubing with a maximum shear rate below 1,000 s⁻¹ to avoid emulsion droplet coalescence. If a manufacturer attempts to deplete bacterial bioburden with a second sterilising-grade filter after inactivation, antigen recovery falls below 70%, and the product fails batch potency parameters. This constraint explains why the API is not terminally heat-sterilised at 121°C, because autoclaving would destroy the haemagglutination activity within seconds.
Field administration from 500 mL multidose bottles imposes additional constraints on the finished oil emulsion. After broaching, the product is used within 8–10 hours at ambient temperatures up to 30°C; beyond this window, microbial ingress risk increases and the emulsion begins to separate. The withdrawal needle gauge should not exceed 18 gauge, because larger bores increase shear and cause localised droplet coalescence near the rubber stopper. Vaccination crews typically attach a draw-off spike with a built-in 200 µm vented filter, and the bottle is protected from direct sunlight because ultraviolet exposure at 254 nm can reduce EDSV titre by more than 1 log2 within 30 min. In-use stability testing follows the protocol for a repeated-dose container, with sampling at 0, 4, 8, and 12 hours and acceptance criteria of no visible creaming, no pH drift beyond 0.2 pH units, and no loss of NDV haemagglutination titre greater than 1 log2.
Competitive Combined Newcastle Disease and Egg Drop Syndrome Vaccine,Inactivated Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
The product is presented as a bivalent inactivated antigen concentrate intended for downstream formulation into finished veterinary dosage forms, including oil-emulsion injections, aqueous solutions, oral powders, granules, premixes, capsules, and tablets where national authorization permits. The Newcastle disease component is based on the lentogenic LaSota strain propagated in specific-pathogen-free embryonated chicken eggs; the egg drop syndrome component is based on the EDS-76 virus strain propagated in duck embryo fibroblasts or allantoic fluid. After harvest, the clarified allantoic or cell-culture pool is concentrated and inactivated. The term “Veterinary Grade API” indicates that the material is not a ready-to-administer vaccine: it is an active antigen intermediate requiring further formulation with sterile diluents, adjuvants, stabilizers, or preservatives according to the registered final-product dossier. No universal numerical model code exists; the manufacturer assigns the model designation ND-EDS-API-BVL to the bulk antigen stream, while the finished marketing authorization number remains the binding regulatory identifier. This distinction is operationally important because an API release certificate is not equivalent to a finished vaccine batch release certificate.
As a liquid bulk, the material is a milky white to off-white suspension with a pH of 6.8–7.4, osmolality of 280–320 mOsm/kg, and density of 1.00–1.08 g/mL. As a lyophilized or spray-dried intermediate, residual moisture is typically controlled at ≤ 3.0% by Karl Fischer titration according to Ph. Eur. 2.5.12. Liquid bulk must be stored at 2–8°C and must not be frozen; freezing of the aqueous antigen pool can produce aggregated viral glycoprotein that reduces haemagglutination titre and interferes with downstream emulsion droplet formation. The container system is normally high-density polyethylene or Type I glass; compatibility with polyvinyl chloride bags should be avoided because residual formaldehyde can interact with flexible bag additives during extended contact.
Inactivation is performed after clarification and before final formulation. The standard inactivating agent is formaldehyde at 0.05–0.10% (v/v) at 35–37°C for 16–24 h; β-propiolactone is an alternative where regional restrictions on formaldehyde exist, but it is less common for combined Newcastle disease and egg drop syndrome material because EDS-76 haemagglutinin titre can decline more rapidly under the alkaline conditions required for β-propiolactone activation. Inactivation must be validated for each batch volume and protein load. The critical process window is narrow: temperatures above 39°C can denature the haemagglutinin–neuraminidase spikes of Newcastle disease virus and the fibre-knob structures of EDS-76, while temperatures below 34°C can produce incomplete first-order inactivation kinetics. Release confirmation of inactivation requires two blind passages in 9–11-day-old embryonated specific-pathogen-free chicken eggs or susceptible cell culture, with no haemagglutinating activity detected. This is a absence-of-live-virus test, not a surrogate for potency, and it must be accompanied by process validation showing that the pre-inactivation infectivity titre is consistently reduced by a minimum factor of 10⁷ from the starting spiked titre.
Sterility is maintained by aseptic processing rather than terminal sterilization. Heat sterilization, gamma irradiation, or terminal 0.22 µm filtration is generally unsuitable because whole-virus antigen is shear-sensitive and adsorbs to membrane matrices; the resulting haemagglutination titre loss can exceed 0.5 log₂. Production areas are controlled to ISO 14644-1:2015 Class 7 or stricter, with open manipulations conducted under unidirectional airflow. Sterility testing is performed by membrane filtration or direct inoculation using soybean-casein digest medium and thioglycollate medium according to Ph. Eur. 2.6.1. Bacterial endotoxins are controlled by the limulus amoebocyte lysate method according to Ph. Eur. 2.6.14; a typical bulk limit is ≤ 20 EU per completed dose equivalent, although the registered limit is product-specific. Absence of live virus, not sterility, is the primary safety separation from live antigen intermediates.
Release controls for the bivalent API include identity, pre-inactivation infectivity titre, post-inactivation absence of live virus, sterility, endotoxin, pH, osmolality, protein content, residual moisture where dried, residual free formaldehyde, and immunogenic potency. For in-process control, Newcastle disease virus pre-inactivation titre is commonly expressed in EID₅₀ and should be not less than 10⁸.⁵ EID₅₀ per millilitre before formaldehyde addition. EDS-76 pre-inactivation titre is commonly not less than 10⁷.⁰ TCID₅₀ per millilitre or a minimum haemagglutination titre of 2⁸ per 25 µL. Potency of the inactivated components is demonstrated by haemagglutination-inhibition serology in specific-pathogen-free chickens at 21 days after vaccination; a typical Newcastle disease response is ≥ 4 log₂ HI titre, while a typical EDS-76 response is ≥ 6 log₂. These limits are not universal; each registration dossier sets binding values, and the API user must verify that the incoming bulk titre is sufficient to withstand adjuvant loading, mixing shear, and drying losses.
| Parameter | Typical window | Reference method |
|---|---|---|
| Appearance | milky white to off-white suspension, free of visible foreign matter | visual inspection |
| pH | 6.8–7.4 | Ph. Eur. 2.2.3 |
| Osmolality | 280–320 mOsm/kg | Ph. Eur. 2.2.35 |
| Sterility | no growth after 14 days | Ph. Eur. 2.6.1 |
| Bacterial endotoxins | ≤ 20 EU per dose equivalent | Ph. Eur. 2.6.14 |
| Residual free formaldehyde | ≤ 0.05% (w/v) in finished product; bulk may be higher pending diafiltration or neutralisation | manufacturer-validated compendial method |
| Residual moisture, lyophilized powder | ≤ 3.0% | Ph. Eur. 2.5.12 |
The values in this table represent typical industrial release windows, not a harmonized pharmacopoeial specification. Published data for this specific combined antigen in tablet or capsule configurations is limited; formulation scientists should treat the above liquid-bulk parameters as starting points and revalidate after each drying and compression step.
Liquid injection and aqueous solution routes preserve the inactivated whole virus antigen most effectively. The standard parenteral presentation is a water-in-oil emulsion prepared with light mineral oil, sorbitan oleate, and polysorbate 80. Droplet size distribution is measured by laser diffraction according to ISO 13320:2020; a common receiving target is D₉₀ ≤ 20 µm, with viscosity of 20–60 mPa·s at 25°C to maintain syringability through automated hatchery injectors. High-shear rotor-stator mixing above 15,000 rpm should be limited because Newcastle disease virus haemagglutinin and EDS-76 fibre-knob glycoproteins are shear-sensitive. Repeated passes through a rotor-stator device can lower haemagglutination titre by more than 0.5 log₂; a single emulsification pass at 10,000–12,000 rpm for 3–5 min is generally used, followed by particle-size verification and accelerated stability screening at 37°C for phase separation.
Powders, granules, and premixes require lyophilization or spray-drying with trehalose, sucrose, lactose, or skim-milk-derived matrices. For lyophilization, primary drying must remain below the collapse temperature of the selected matrix; trehalose-based formulations often require shelf temperature below -30°C during primary drying and condenser temperature below -50°C. Residual moisture must remain below 3.0% to prevent glass-transition collapse and antigen titre loss during storage. Granules and premixes for oral administration may be mixed into feed, but the active antigen is susceptible to acidic gastric degradation in birds. Tablet and capsule presentations present the greatest formulation constraints: direct compression generates localized shear and temperature, while enteric or delayed-release coatings are required to protect the antigen through the avian gastrointestinal tract. Unless an oral solid dosage form is validated by in vitro dissolution and in vivo serology, it is not a suitable primary vaccination route for this inactivated antigen. Published data on the oral delivery of this specific combination in tablet or capsule form is limited; parenteral injection remains the route with the largest body of industrial validation.
Excipient incompatibilities include cationic polymers and high-charge-density adjuvants that can produce antigen–excipient aggregation during formulation. Avoid combination with amine-based additives or strongly alkaline buffer systems because residual formaldehyde can react with primary amine groups, altering antigen surface charge. If aluminum hydroxide is used as an alternative adjuvant, pre-formulation antigen adsorption should be measured by haemagglutination titre in the supernatant after centrifugation at 10,000 × g for 10 min; unvalidated adsorption can leave less than 50% of input haemagglutination titre in the liquid phase. Phenolic preservatives may be less compatible with this API than thiomersal at equivalent antimicrobial concentrations; any preservative change requires revalidation of the final dose form under 2–8°C stability conditions.
Replacement of separate Newcastle disease and egg drop syndrome monovalent inactivated antigens with one bivalent API reduces the number of inactivation cycles, sterile bulk operations, and final emulsion batches required in the manufacturing plant. In layer and breeder vaccination programmes, the combined inactivated product is typically administered at 14–18 weeks of age, after live Newcastle disease virus priming, by subcutaneous or intramuscular injection at 0.3–0.5 mL per bird. The inactivated Newcastle disease component produces sustained humoral antibody titres through peak egg production, while the EDS-76 component protects against egg-production losses and poor eggshell quality associated with egg drop syndrome virus infection. Compared with live Newcastle disease vaccination, the inactivated combined API does not replicate, does not spread between birds, and does not induce post-vaccinal respiratory reactions in extensively housed flocks. It cannot, however, provide the rapid mucosal IgA response of live lentogenic priming and is unsuitable for mass spray or drinking-water delivery.
The main formulation difference from a finished oil-emulsion Newcastle disease and egg drop syndrome vaccine is the absence of ready-to-use adjuvant and preservative. The API user must add the oil phase, aqueous phase, surfactant system, and any preservative under controlled conditions; this provides flexibility in final dose volume and adjuvant type but requires in-house formulation and aseptic capacity. Compared with products containing additional antigens such as infectious bronchitis virus or avian metapneumovirus, the bivalent ND-EDS API has a lower antigenic input burden, which can reduce the likelihood of antigenic interference demonstrated by depressed haemagglutination-inhibition responses to one component. Compared with monovalent Newcastle disease or EDS-76 API, the bivalent stream must be blended from two independently titre-controlled bulks before inactivation; failure to adjust for pre-inactivation titre drift in embryonated egg batches can produce batch-to-batch antibody response variation of 0.3–0.5 log₂ at the same injection volume.
| Attribute | Combined ND-EDS inactivated API | Monovalent ND inactivated API | Finished oil-emulsion ND-EDS vaccine |
|---|---|---|---|
| Active payload | two inactivated viruses | one inactivated virus | two inactivated viruses plus adjuvant and preservative |
| Field readiness | requires formulation before use | requires formulation before use | ready for injection |
| Storage | 2–8°C; do not freeze | 2–8°C; do not freeze | 2–8°C; do not freeze |
| Primary comparative advantage | single bulk pool and single inactivation cycle | simpler release panel | no downstream compounding required |
| Primary constraint | must revalidate drying, tableting, or encapsulation | does not protect against EDS-76 | fixed adjuvant system and dose volume |
Batch processing of the bivalent API typically proceeds through a stainless-steel blending vessel with bottom-mounted turbine agitation at 120 rpm for 30 min after completion of both inactivation reactions. This low-shear mixing step is intended to evenly distribute the two antigen pools without generating a stable foam, because foam can denature surface glycoprotein at the air–liquid interface. Process bottlenecks observed on production lines include incomplete neutralization of residual formaldehyde before blending, which can suppress post-vaccination haemagglutination-inhibition titre by 0.3–0.7 log₂; incomplete pH adjustment after blending, which can shift the net surface charge of the virus particles and alter emulsion stability; and failure to verify EDS-76 haemagglutination titre after inactivation, which can go undetected if only Newcastle disease potency is monitored. The bivalent API therefore requires a dual release potency panel and separate stability-indicating assays for both viral antigens.
